Physician profile
Scott A Lawrence
NPI 1407874076
$365.92
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $102 · 2023: $75.46 · 2024: $48.26 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $93.21 | 2022-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $35.77 | 2022-2025 | |
| Astellas Pharma US INC | $29.84 | 2022-2024 | Veozah |
| Exact Sciences Corporation | $28.93 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $26.98 | 2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $24.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.22 | 2022 | |
| Harmony Biosciences LLC | $20.43 | 2023 | Wakix |
| Otsuka America Pharmaceutical, INC. | $19.64 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $15.00 | 2023 | |
| Novo Nordisk INC | $13.76 | 2025 | |
| Lilly USA, LLC | $13.50 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $13.07 | 2022 | |
| Phathom Pharmaceuticals, INC. | $9.18 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.